Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.43 per common share. The dividend is payable on January 15, 2026 to shareholders of record as of December 15, 2025.

Thermo Fisher Scientific (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings for $8.875 billion in cash plus potential earnouts and follow‑up payments.

Clario, with ~4,000 employees and expected $1.25 billion revenue in 2025, provides endpoint data solutions that supported ~70% of FDA drug approvals over the past decade. Thermo Fisher expects the deal to be immediately accretive to adjusted EPS by $0.45 in year one, to deliver ~$175M adjusted operating income from synergies by year five, and to grow the business at high single digits under Thermo Fisher ownership. Close is expected by mid‑2026, subject to approvals; funding will include debt financing and cash on hand.

Thermo Fisher Scientific (NYSE: TMO) reported Q3 2025 results for the quarter ended September 27, 2025. Revenue rose 5% to $11.12 billion with organic revenue growth of 3%. GAAP diluted EPS was $4.27 (in-line year‑over‑year) and adjusted EPS grew 10% to $5.79. Adjusted operating margin improved to 23.3% and adjusted operating income was $2.59 billion. The company completed acquisitions of a Filtration and Separation business and Sanofi’s Ridgefield sterile fill‑finish site, repurchased $1.0 billion of stock, launched several products, received an FDA approval for an Oncomine Dx test, and announced a strategic collaboration with OpenAI.

Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with OpenAI on October 16, 2025 to embed OpenAI APIs across product development, service delivery, customer engagement and operations.

Key initiatives include applying OpenAI to Thermo Fisher’s PPD clinical research business to shorten clinical trial cycle time, integrating AI into the Accelerator Drug Development solution across Phase I–III and manufacturing, and rolling out ChatGPT Enterprise to employees to build AI fluency.

Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science, has scheduled its Q3 2025 earnings release and conference call for Wednesday, October 22, 2025. The financial results will be released before market opening, followed by a conference call at 8:30 a.m. ET.

Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 internationally, using access code 761271. A live webcast will be available on the company's investor relations website. The earnings materials and call replay will remain accessible through February 1, 2026.

Thermo Fisher Scientific (NYSE: TMO) has announced the pricing of a $2.5 billion senior notes offering across four tranches with different maturities and interest rates. The offering includes: $500 million of 4.200% notes due 2031, $750 million of 4.473% notes due 2032, $750 million of 4.794% notes due 2035, and $500 million of 4.894% notes due 2037.

The offering is expected to close around October 7, 2025. The company plans to use the proceeds for general corporate purposes, including potential acquisitions, debt refinancing, working capital, capital expenditures, or share repurchases. J.P. Morgan Securities, ING Financial Markets, Mizuho Securities USA, and Scotia Capital are serving as joint book-running managers for the offering.

Thermo Fisher Scientific (NYSE:TMO) has completed the acquisition of Sanofi's sterile fill-finish and packaging facility in Ridgefield, New Jersey. The strategic move expands TMO's U.S. manufacturing capabilities within its Laboratory Products and Biopharma Services segment.

The deal includes retaining over 200 experienced employees and continuing to manufacture Sanofi's therapies at the site while expanding capacity for other pharma and biotech customers. The Ridgefield facility joins TMO's existing U.S. sterile fill-finish network, which includes sites in Greenville, North Carolina and Plainville, Massachusetts.

The acquisition strengthens TMO's Accelerator™ Drug Development 360° CDMO and CRO solutions, enhancing its pharmaceutical value chain services for emerging biotech and biopharma companies.

Thermo Fisher Scientific (NYSE: TMO) has completed its acquisition of Solventum's Purification & Filtration business for $4.0 billion in cash. The acquired business, now renamed as Thermo Fisher's Filtration and Separation business, will be integrated into the Life Sciences Solutions segment.

The acquisition strengthens TMO's bioproduction portfolio with advanced filtration technologies and expands its reach into industries requiring ultra-pure water. The acquired business is expected to generate $750 million in revenue for 2025 and achieve mid- to high-single digit organic growth. The transaction is projected to be dilutive to adjusted EPS by $0.06 in the first year, with expected synergies of $125 million in adjusted operating income by year five.

Solventum (NYSE: SOLV) has completed the sale of its Purification & Filtration (P&F) business to Thermo Fisher Scientific (NYSE: TMO) for $4.0 billion in cash. The company will receive net proceeds of $3.4 billion, primarily allocated to debt reduction.

Following this strategic divestiture, Solventum has updated its FY2025 guidance, projecting organic sales growth of 2.0-3.0% and raising its adjusted EPS range to $5.88-$6.03. The company expects operating margins at the high end of 20-21% range and reduced net interest expense of $400 million, down from $450 million previously forecasted.